Humanization of fibroblast growth factor 1 single‐chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells. Issue 6 (24th March 2018)

• Record Type: Journal Article
• Authors: He, Xiao‐Xiao; Du, Shuang; Gao, Shi‐Qian; Chen, Jing‐Ying; Cao, Ran‐Juan; Xing, Zhen‐Kai; Kazim, Alia Rizvi Syeda; Yu, Hua‐Li; Zheng, Qing‐Chuan; Zhu, Xiao‐Juan
• Is Part Of: Journal of cellular and molecular medicine. Volume 22:Issue 6(2018)
• Page Start: 3259
• Page End: 3263
• Publication Date: 2018-03-24
• Subjects: antibody humanization -- cancer treatment -- fibroblast growth factor 1 -- monoclonal antibody -- single‐chain variable fragment; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13547
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Single‐chain variable fragment (scFv) antibodies are the smallest immunoglobulins with high antigen‐binding affinity. We have previously reported that fibroblast growth factor 1 played pivotal roles in cancer development and generated a mouse scFv (mscFv1C9) could effectively prohibit cancer cell proliferation in vitro and in vivo. Here, we further humanized this scFv (hscFv1C9) using a structure‐guided complementarity determining region grafting strategy. The purified hscFv1C9 maintained similar antigen‐binding affinity and specificity as mscFv1C9, and it was capable of inhibiting growth of different tumours in vitro and in vivo. These data strongly suggested that hscFv1C9 has antitumour potentials.